Support Australian
tech for good

Adelaide-based company TekCyte is seeking expressions of interest to invest in expanding their revolutionary medtech BIOINVISIBLE – a drug-free medical device coating that could curb global rates of infection from implanted devices and potentially save thousands of lives each year

Their story

TekCyte emerged from the Cooperative Research Centre (CRC) for Cell Therapy Manufacturing, established July 2013.

Now a public unlisted company, TekCyte is led by CEO Dr Tony Simula and a Board of Directors who have each founded a successful biotech company.

TekCyte has a proven history of creating and delivering solutions for the medtech industry and are a trusted supply partner for medical device companies world-wide.

The Problem

Commonly used medical devices such as catheters are very prone to bacterial build up, or biofilm, leading to infections that can enter the blood and become life-threatening.

Australian hospitals experience several thousand such infections each year, causing hundreds of deaths and costing Medicare in excess of $40 million per year.

The World Health Organisation has identified infection as one of their top global concerns due to the growing number of antibiotic resistant bacteria and they anticipate by 2050 there will be 10 million deaths across the planet each year if something isn’t done.

TekCyte have developed a long-term solution to address this. A drug free coating that can be applied to medical implants called BIOINVISIBLE, which acts as a physical barrier and shown to prevent biofilm.

The Opportunity

Interest is mounting for medtech following a world-wide slump during the pandemic – and with BIOINVISIBLE already showing a range of potential benefits that could extend beyond the medical world, there is a bright future for this homegrown and life-saving invention.

TekCyte has already received feedback and support from surgeons and medical professionals that BIOINVISIBLE could transform the industry.

The industry and market opportunity is growing at a rapid rate - the time to back and express interest in investing in TekCyte is now.

Proof it works

Investor EOI process

The Expression
of Interest Process

TekCyte have partnered with the Industry Commercialisation Agency by Small and Mighty Group to run an expression of interest campaign, offering the opportunity to invest in this pioneering company.

Here’s how to get involved and what to expect:

  1. Complete the details in the EOI form and a team member will review your submission (note that completing the EOI does not commit you to or guarantee investment with TekCyte)

  2. You will be invited to attend an exclusive information session to learn more about TekCyte and what being an investor could mean

  3. A representative will contact you to discuss the next steps in investment opportunities with TekCyte

Remember to ask questions, read all information given carefully, and seek independent financial advice before committing yourself to any investment.

Request a copy of the TekCyte Infomation Memorandum

PLEASE NOTE OUR 2023 EOI CAMPAIGN HAS NOW ENDED.